Johnson & Johnson Acquires Firefly Bio For $1 Billion To Enhance Oncology Pipeline

Johnson & Johnson has agreed to acquire Firefly Bio for $1 billion in cash, expanding its oncology pipeline with a novel cancer-targeting technology focused on KRAS-driven tumors. The deal centers on Firefly Bio’s Firelink degrader antibody conjugate platform, which combines antibody-drug conjugate delivery with targeted protein degradation to more precisely attack cancer cells while limiting damage to healthy tissue. The transaction is expected to close pending regulatory approvals.

Summary of transaction details:

• Deal Type: Acquisition
• Transaction Amount: $1,000,000,000
• Company Headquarters: New Brunswick, New Jersey

Firefly Bio specializes in innovative cancer therapies targeting KRAS mutations, which are particularly challenging in oncology. The acquisition will enhance Johnson & Johnson's capability to develop next-generation therapies for hard-to-treat solid tumors, further strengthening their oncology pipeline.